Debanjana Chatterjee
Stock Analyst at Jones Trading
(4.58)
# 748
Out of 5,182 analysts
20
Total ratings
66.67%
Success rate
25.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics | Maintains: Buy | $52 → $63 | $40.45 | +55.75% | 2 | Apr 28, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Buy | $64 → $95 | $69.13 | +37.42% | 3 | Apr 17, 2026 | |
| HYFT MindWalk Holdings | Initiates: Buy | $5 | $1.25 | +301.61% | 1 | Apr 16, 2026 | |
| ABCL AbCellera Biologics | Initiates: Buy | $11 | $4.59 | +139.65% | 1 | Apr 10, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $25 → $24 | $14.38 | +66.90% | 1 | Mar 19, 2026 | |
| NTLA Intellia Therapeutics | Upgrades: Buy | $29 | $13.87 | +109.08% | 3 | Mar 4, 2026 | |
| ARMP Armata Pharmaceuticals | Initiates: Buy | $15 | $9.85 | +52.28% | 1 | Jan 5, 2026 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $16.89 | +42.10% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $7.90 | +241.77% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $3.54 | +1,001.69% | 1 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 | $26.66 | +12.53% | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $14.15 | +62.54% | 1 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $30.02 | +53.23% | 1 | Sep 19, 2024 |
Sionna Therapeutics
Apr 28, 2026
Maintains: Buy
Price Target: $52 → $63
Current: $40.45
Upside: +55.75%
Spyre Therapeutics
Apr 17, 2026
Maintains: Buy
Price Target: $64 → $95
Current: $69.13
Upside: +37.42%
MindWalk Holdings
Apr 16, 2026
Initiates: Buy
Price Target: $5
Current: $1.25
Upside: +301.61%
AbCellera Biologics
Apr 10, 2026
Initiates: Buy
Price Target: $11
Current: $4.59
Upside: +139.65%
Trevi Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $25 → $24
Current: $14.38
Upside: +66.90%
Intellia Therapeutics
Mar 4, 2026
Upgrades: Buy
Price Target: $29
Current: $13.87
Upside: +109.08%
Armata Pharmaceuticals
Jan 5, 2026
Initiates: Buy
Price Target: $15
Current: $9.85
Upside: +52.28%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $16.89
Upside: +42.10%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $7.90
Upside: +241.77%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $3.54
Upside: +1,001.69%
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $26.66
Upside: +12.53%
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $14.15
Upside: +62.54%
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $30.02
Upside: +53.23%